106 related articles for article (PubMed ID: 17016218)
1. Nonsurgical management of osteolysis: challenges and opportunities.
Talmo CT; Shanbhag AS; Rubash HE
Clin Orthop Relat Res; 2006 Dec; 453():254-64. PubMed ID: 17016218
[TBL] [Abstract][Full Text] [Related]
2. The biology of aseptic osteolysis.
Holt G; Murnaghan C; Reilly J; Meek RM
Clin Orthop Relat Res; 2007 Jul; 460():240-52. PubMed ID: 17620815
[TBL] [Abstract][Full Text] [Related]
3. The cellular and molecular biology of periprosthetic osteolysis.
Purdue PE; Koulouvaris P; Potter HG; Nestor BJ; Sculco TP
Clin Orthop Relat Res; 2007 Jan; 454():251-61. PubMed ID: 16980902
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of receptor activator of nuclear factor-kappaB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty.
Wang CT; Lin YT; Chiang BL; Lee SS; Hou SM
Biomaterials; 2010 Jan; 31(1):77-82. PubMed ID: 19781765
[TBL] [Abstract][Full Text] [Related]
5. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Schwarz EM; Benz EB; Lu AP; Goater JJ; Mollano AV; Rosier RN; Puzas JE; Okeefe RJ
J Orthop Res; 2000 Nov; 18(6):849-55. PubMed ID: 11192243
[TBL] [Abstract][Full Text] [Related]
6. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
7. Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis.
Koulouvaris P; Ly K; Ivashkiv LB; Bostrom MP; Nestor BJ; Sculco TP; Purdue PE
J Orthop Res; 2008 Jan; 26(1):106-16. PubMed ID: 17729302
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
9. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
10. The role of macrophages in osteolysis of total joint replacement.
Ingham E; Fisher J
Biomaterials; 2005 Apr; 26(11):1271-86. PubMed ID: 15475057
[TBL] [Abstract][Full Text] [Related]
11. The basic science of periprosthetic osteolysis.
Archibeck MJ; Jacobs JJ; Roebuck KA; Glant TT
Instr Course Lect; 2001; 50():185-95. PubMed ID: 11372314
[TBL] [Abstract][Full Text] [Related]
12. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
13. Is there another possible approach to inhibit wear particles-induced inflammatory osteolysis?
Liu YP; Yu GR; Li K; Yuan F
Med Hypotheses; 2011 Feb; 76(2):280-2. PubMed ID: 21067868
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB modulators in osteolytic bone diseases.
Xu J; Wu HF; Ang ES; Yip K; Woloszyn M; Zheng MH; Tan RX
Cytokine Growth Factor Rev; 2009 Feb; 20(1):7-17. PubMed ID: 19046922
[TBL] [Abstract][Full Text] [Related]
15. [Involvement of immunogenetic factors in the development of periprosthetic osteolysis].
Gallo J; Mrázek F; Petrek M
Acta Chir Orthop Traumatol Cech; 2007 Aug; 74(4):247-52. PubMed ID: 17877940
[TBL] [Abstract][Full Text] [Related]
16. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial.
Sköldenberg O; Rysinska A; Eisler T; Salemyr M; Bodén H; Muren O
BMC Musculoskelet Disord; 2016 Apr; 17():174. PubMed ID: 27108405
[TBL] [Abstract][Full Text] [Related]
18. [Periprosthetic osteolysis following the total hip arthroplasty].
Zu G; Bi DW; Fej J
Zhongguo Gu Shang; 2008 Mar; 21(3):240-2. PubMed ID: 19105458
[TBL] [Abstract][Full Text] [Related]
19. Osteoclast culture and resorption assays.
Bradley EW; Oursler MJ
Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
[TBL] [Abstract][Full Text] [Related]
20. Current concepts in osteolysis.
Ollivere B; Wimhurst JA; Clark IM; Donell ST
J Bone Joint Surg Br; 2012 Jan; 94(1):10-5. PubMed ID: 22219240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
